A total of 25 patients, including 20 patients with SS, four patients with MF, and one patient with CD4+ CTCL (neither MF nor SS), have been treated at the 10 preplanned ascending dose levels (0.0001–10 mg/kg). The gene discussed is CD4; the disease is synovial sarcoma.